By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Mary Jane's PostMary Jane's Post
  • Tech
  • Science
  • Culture & Arts
  • Press Releases
  • More
    • About Us
    • Advertise
    • Monthly Give-Away
    • Partner With Us
  • Join UsNew
Reading: Pebble Engages MD Anderson to Evaluate Multi-Cannabinoid Formulations in Ovarian Cancer
Share
0

No products in the cart.

Aa
Mary Jane's PostMary Jane's Post
Aa
  • Press Releases
  • Submit News
  • Join UsNew
Search
  • Topics
    • Business
    • Cannabis Community
    • Cannabis Tech
    • Culture & Arts
    • Industry Leaders
    • Press Releases
  • About Us
    • Guest Columnist
    • Ambassador
    • Partner With Us
Have an existing account? Sign In
Follow US
©2018 - 2022 TheRkive Entertainment Group, LLC. All Rights Reserved.
Mary Jane's Post > Press Releases > Pebble Engages MD Anderson to Evaluate Multi-Cannabinoid Formulations in Ovarian Cancer
Press Releases

Pebble Engages MD Anderson to Evaluate Multi-Cannabinoid Formulations in Ovarian Cancer

Business Wire
Posted Business Wire February 16, 2022
Updated 2022/02/16 at 4:20 PM
2 Min Read
SHARE

Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care.

DALLAS–(BUSINESS WIRE)–Pebble Global Holdings (aka “Pebble Life Sciences” or “Pebble”), a privately held Texas-based leader in non-psychotropic cannabinoid research for drug development, today announced that a sponsored research program entitled “Evaluation of Multi-Cannabinoid Formulations in Ovarian Cancer” was initiated in 2020 and presently exists between Pebble and MD Anderson Cancer Center (“MD Anderson”). MD Anderson is one of the world’s most respected centers devoted exclusively to cancer patient care, education, prevention, research and ranked No. 1 in cancer in the U.S. News & World Report’s 2021-2022 annual “Best Hospitals.”

Pebble Video Cannabis News
Cannabis News

Despite being one of the most researched, ovarian cancer is the leading cause of gynecological cancer in the US and second most globally. It is the fifth leading cause of cancer death in US women, with 22,000 diagnosed in 2021, resulting in 14,000 deaths. 75% of patients are “advanced” at initial diagnosis, with 1 in 6 dying within 90 days and treatment limited by severe adverse effects from the current standard of care.

“Our team has thoroughly enjoyed working with MD Anderson the past two years on this novel therapy. We’re excited to continue with MD Anderson, to improve cancer treatment standard of care. Pebble’s non-THC, non-psychotropic approach permits a regulatory drug pathway that allows both domestic and global distribution, so we can help as many suffering women as possible,” says Pebble Founder & CEO – Patrick Moran.

About Pebble Life Sciences

Pebble is the cannabinoid-focused subsidiary of AcquiFlow LLC (est. 2014 as the “first open, legal and transparent” Texas-based cannabis company; whose holdings include a patent estate in non-consumable industrial hemp genetics). Pebble has established a patent estate sufficient to help fuel a large cap company’s marketing, sales and distribution channels. These filings protect both Pebble’s cannabinoid-compound formulation process and the initial successful prototype. Pebble OTC product versions are available for purchase at www.pebble.life/shop, maintain pharmaceutical variance standards, and provide independent third-party testing for every batch.

About MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center (colloquially MD Anderson Cancer Center) is a comprehensive cancer center in Houston, Texas. It is the largest cancer center in the U.S. and one of the original three comprehensive cancer centers in the country. It is both a degree-granting academic institution and a cancer treatment and research center located at the Texas Medical Center in Houston. It is affiliated with The University of Texas Health Science Center at Houston.

Contacts

Media Contact: Travis Merchant (512) 662-9156 [email protected]
Investor Contact: Andrew Baker (602) 418-1250 [email protected]
Website: www.pebble.life
Tweets by: @pebblewellness

LinkedIn: https://www.linkedin.com/company/pebble-wellness/

You Might Also Like

Heritage Cannabis Reports 2021 Year-End Financial Results

Flora Growth Launches Vessel in Canada; Signs Deal With Ontario Cannabis Store and Launches Vesselbrand.ca

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

Houston Area Army Veteran Reclaims Life, Eliminates Opioid Use with Medical Cannabis

Heritage Cannabis Announces Corporate Update and Highlights Significant Sales Growth, Market Share and Growing Distribution

TAGGED: Business Wire
Business Wire February 16, 2022
Share this Article
Facebook Twitter Pinterest LinkedIn Reddit
Share
Business Wire
Posted by Business Wire
Follow:
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy, and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.
Previous Article Fluence Launches SPYDR 2h, Enabling Commercial Cannabis Cultivators to Produce Higher Crop Yields
Next Article Botanacor Laboratories and Agricor Laboratories Name a New Digital Officer and Senior VP for Information Technology
- Advertisement -
Ad imageAd image

Stay Connected

Facebook Like
Twitter Follow
Pinterest Pin
Instagram Follow

You Might Also Like

Heritage Cannabis Reports 2021 Year-End Financial Results

May 12, 2022

Flora Growth Launches Vessel in Canada; Signs Deal With Ontario Cannabis Store and Launches Vesselbrand.ca

May 11, 2022

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

May 11, 2022

Houston Area Army Veteran Reclaims Life, Eliminates Opioid Use with Medical Cannabis

May 11, 2022
Mary Jane's PostMary Jane's Post

©2018 - 2022 TheRkive Entertainment Group, LLC. All Rights Reserved.

  • PRIVACY
  • TERMS OF USE
  • CONTRIBUTOR AGREEMENT
  • CONTRIBUTOR GUIDELINES

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Register Lost your password?